Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy von Merz, Maximilian, Dima, Danai, Hashmi, Hamza, Ahmed, Nausheen, Stölzel, Friedrich, Holderried, Tobias A. W., Fenk, Roland, Müller, Fabian, Tovar, Natalia, Oliver-Cáldes, Aina, Rathje, Kristin, Davis, James A., Fandrei, David, Vucinic, Vladan, Kharboutli, Soraya, Baermann, Ben-Niklas, Ayuk, Francis, Platzbecker, Uwe, Albici, Anca-Maria, Schub, Nathalie, Schmitz, Friederike, Shune, Leyla, Khouri, Jack, Anwer, Faiz, Raza, Shahzad, McGuirk, Joseph, Mahmoudjafari, Zahra, Green, Kimberly, Khandanpour, Cyrus, Teichert, Marcel, Jeker, Barbara, Hoffmann, Michele, Kröger, Nicolaus, von Tresckow, Bastian, de Larrea, Carlos Fernández, Pabst, Thomas, Abdallah, Al-Ola, Gagelmann, Nico

Volltext